Compare RANI & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RANI | SRFM |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9M | 117.5M |
| IPO Year | 2021 | 2023 |
| Metric | RANI | SRFM |
|---|---|---|
| Price | $0.68 | $0.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $7.50 | $3.25 |
| AVG Volume (30 Days) | 634.8K | ★ 9.5M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.14 | 45.69 |
| EPS | ★ N/A | N/A |
| Revenue | $1,633,000.00 | ★ $106,557,000.00 |
| Revenue This Year | $274.77 | $25.90 |
| Revenue Next Year | $79.44 | $20.72 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 58.85 | N/A |
| 52 Week Low | $0.39 | $0.84 |
| 52 Week High | $3.87 | $9.35 |
| Indicator | RANI | SRFM |
|---|---|---|
| Relative Strength Index (RSI) | 35.15 | 43.32 |
| Support Level | $0.45 | $0.84 |
| Resistance Level | $0.83 | $1.29 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 20.70 | 20.36 |
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Surf Air Mobility Inc is a regional air mobility platform operating commuter airlines in the United States and expanding an on-demand charter marketplace for passengers in the U.S. and globally. It is also focused on developing a proprietary aviation software, aircraft electrification powertrain technology and services to enable electrification across the regional air mobility sector. The company operates in a single reportable segment, Air Mobility. The Air Mobility segment derives revenue from operating scheduled commercial air service flights, which are sold to the public mainly on a per-seat basis; through subsidized EAS revenue awards from the Department of Transportation; and by operating on-demand flights for customers on an ad-hoc, by request basis.